SARASOTA, Fla. and ATLANTA, Sept. 7,
2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:
INVO), a medical device company focused on commercializing the
world's only in vivo culture system (IVC), INVOcell®, announced
today as the official opening for the Company's second INVO Center
in the United States, based in
Atlanta, Georgia. This new
joint-venture, named "Bloom Fertility, an INVO Center," will focus
on patients in need of advanced fertility care utilizing the
efficient, effective, and affordable INVOcell solution.
Bloom Fertility, an INVO Center, is a partnership between INVO
Bioscience and experienced reproductive specialist Dr. Sue Ellen Carpenter, MD. Dr. Carpenter is noted
for excellence in her field and named a "Top Doctor, Atlanta 2019 and 2020." She is an active
member of the American Society of Reproductive Medicine (ASRM) as
well as the Georgia OB GYN Society, and frequently delivers
lectures across the country, having published more than a dozen
papers on reproduction and fertility.
Dr. Carpenter commented, "This is an exciting time for
patients in Atlanta that suffer
from infertility. Bloom Fertility, an INVO Center, will offer the
INVOcell solution for the many patients that remain underserved,
and do so with a connected, intimate experience. I look
forward to leveraging this technology through our new center, to
bring the joy of parenthood to so many that have been dissuaded by
the lack of affordable care or wary of traditional laboratory
methods."
Steve Shum, CEO of INVO
Bioscience, commented, "We are thrilled today to officially open
our Atlanta-based INVO Center.
Bloom Fertility, an INVO Center, will look to advance our core
mission of improving access to advanced fertility services for the
many patients in Atlanta and the
surrounding region."
The Atlanta-based INVO Center
becomes the second INVO Center to open and will begin seeing
patients immediately and perform initial INVOcell treatment cycles
in the month of October 2021. Earlier
this month, INVO Bioscience announced the opening of the first INVO
Center based in Birmingham, Alabama. Additional INVO Centers
are scheduled to open, including one in Monterrey, Mexico for this year as well as the
San Francisco Bay Area.
Shum concluded, "We have seen early success from our recently
opened Birmingham-based INVO Center, with patient appointments and
expected treatment cycles ahead of original expectations. We are
excited to now open Atlanta and
lead the democratization of advanced fertility treatment, which can
be made possible by the revolutionary INVOcell solution."
Bloom Fertility, an
INVO Center is located at 6 Concourse
Parkway, Suite 250, Atlanta GA
30328, PH# 678-597-9933
About INVOcell
The INVOcell procedure is the first in-vivo culture (IVC) system
in the world used for the incubation of eggs and sperm during
fertilization and early embryo development within the body, as an
alternative to conventional In Vitro Fertilization (IVF) and
Intrauterine Insemination (IUI). Through its in vivo approach,
INVOcell offers patients a more natural and intimate experience
with comparable results at a lower cost.
About INVO Bioscience
We are a medical device company focused on creating simplified,
affordable treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-announces-official-opening-of-bloom-fertility-an-invo-center-in-atlanta-301369987.html
SOURCE INVO Bioscience, Inc.